Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

35.61 +0.78 (+2.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis Inc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
2 Under-the-Radar Biotech Stocks to Buy in 2023
These stocks may soon start turning heads with their revenue growth. 
Via The Motley Fool
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb and Exelixis, Inc.
Via Business Wire
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
Looking Into Exelixis's Return On Capital Employed
Via Benzinga
Exelixis (EXEL) Q4 2022 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2022. 
Via The Motley Fool
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These companies could grow in prominence in the coming years. 
Via The Motley Fool
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Earnings Outlook For Exelixis
Via Benzinga
3 No-Brainer Stocks to Buy Right Now for Less Than $25
All three healthcare stocks are showing solid long-term potential. 
Via The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
From Exelixis, Inc.
Via Business Wire
6 Analysts Have This to Say About Exelixis
Via Benzinga
Is Exelixis Stock a Buy Now?
Don't be too quick to dismiss this company as a one-trick pony. 
Via The Motley Fool
What 5 Analyst Ratings Have To Say About Exelixis
Via Benzinga
Where Exelixis Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
Via Benzinga
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
From Exelixis, Inc.
Via Business Wire
Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue
Via Benzinga
Exelixis Announces Update on Patent Litigation with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
7 Biotech Stocks That Will Make You Rich in 10 Years
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years. 
Via InvestorPlace
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
From Exelixis, Inc.
Via Business Wire
Four Undervalued Healthcare Stocks for 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc. 
Via MarketBeat
Exposures COVID-19
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —
From Exelixis, Inc.
Via Business Wire
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
From Exelixis, Inc.
Via Business Wire
2 Beaten-Down Growth Stocks to Buy Before the Bull Run
These could become hot buys once investors pivot back to growth stocks. 
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint. 
Via The Motley Fool
Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip
These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite. 
Via The Motley Fool
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study  
Via Benzinga
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.